Endocrine Abstracts

Context: Denosumab, a fully human monoclonal antibody that inactivates receptor activator of nuclear factor k-B ligand (RANKL), is used for osteoporosis treatment because of its potent anti-resorptive properties. Due to its reversible mode of action, bone resorption increases rapidly after its discontinuation and is accompanied by a quick loss of bone mineral density. Spontaneous vertebral fractures at this period have been recognized as secondary to the rebound of bone resorp...

Introduction: Denosumab reduces bone resorption, increases BMD, and reduces fracture risk. Denosumab discontinuation (DD) induces an increase of B-crosslaps above baseline values for two years, and a decrease of BMD values. This rebound effect is associated with spontaneous clinical vertebral fractures (SCVF) in close to 15% of patients considering a follow-up of 2 years without taking another osteoporosis treatment. Prescribing a bisphosphonate or SERMs at DD would prevent th...

Background: Graves’ disease (GD) typically manifests as an autoimmune hyperfunction of both thyroid lobes. Less than 10 cases of unilateral GD have been described, and the pathophysiology of unilateral GD remains unknown. Co-existence of malignancy has never been reported. We report a case of GD of the left lobe with simultaneous discovery of a papillary carcinoma within the hyperfunctioning lobe.Case description: A 49-year-old patient of Middle-Eas...